Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.3273
Nov 17 • 3:58 PM ET Dollar change-0.0145 Percentage change(-4.24%)
Aftermarket Close
0.3373
Aftermarket • 7:36 PM ET Dollar change+0.0100 Percentage change(3.06%)
Index
-
Market Cap
6.54M
Enterprise Value
12.90M
Income
-40.59M
Sales
0.00M
Book/sh
-0.11
Cash/sh
0.05
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
4
IPO
Nov 12, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
7.27
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.34
Current Ratio
0.34
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-3.91
EPS next Y
-0.49
EPS next Q
-0.15
EPS this Y
60.35%
EPS next Y
80.48%
EPS next 5Y
58.27%
EPS past 3/5Y
46.00% 76.03%
Sales past 3/5Y
- -
EPS Y/Y TTM
61.31%
Sales Y/Y TTM
-
EPS Q/Q
72.86%
Sales Q/Q
-
Insider Own
39.64%
Insider Trans
3.01%
Inst Own
2.95%
Inst Trans
14.05%
ROA
-313.56%
ROE
-1797.61%
ROIC
-991.94%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-26.26%
SMA50
-50.22%
SMA200
-75.96%
Trades
Shs Outstand
16.89M
Shs Float
12.07M
52W High
9.75 -96.64%
52W Low
0.34 -2.79%
Volatility
13.64% 11.31%
ATR (14)
0.05
RSI (14)
23.48
Beta
-1.44
Rel Volume
0.07
Avg Volume
2.53M
Volume
183,164
Perf Week
-12.53%
Perf Month
-45.46%
Perf Quarter
-69.41%
Perf Half Y
-81.61%
Perf YTD
-88.60%
Perf Year
-96.51%
Perf 3Y
-99.27%
Perf 5Y
-99.77%
Perf 10Y
-100.00%
Prev Close
0.34
Price
0.33
Change %
-4.24%
Consensus
Strong Buy
Avg. Price Target
$7.00
Implied Upside
+2,038.7%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 22, 2026Upgrade
HH.C. Wainwright
Neutral → Buy$11+3,260.8%
Apr 10, 2025Downgrade
BNS logoBScotiabank
Sector Outperform → Sector Perform
Apr 10, 2025Downgrade
HH.C. Wainwright
Buy → Neutral
Mar 14, 2024Initiated
BNS logoBScotiabank
Sector Outperform$13+3,871.9%
Feb 08, 2024Initiated
JEF logoJJefferies
Buy$15+4,483.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angel MatthewCEO and PresidentMar 24 '26Buy2.16231,482500,001231,482Jun 23 04:56 PM
Angel MatthewCEO and PresidentMar 24 '26Buy2.16231,482500,001231,482Mar 25 05:32 PM
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
PresidentDr. Matthew Angel Ph.D.
CFOMs. Stephanie Horn-Warnock
Head of Business DevelopmentDr. Andrew Fang Ph.D.